Hyperlipidaemia and cardiovascular disease - Newer antihyperglycaemic agents and cardiovascular disease

Current Opinion in Lipidology

Volumn 24, Issue 2, 2013, Pages 189-190

  Peter, Rajesh ^a,b   Bajwa, Hammad ^b   Anthony, Sony ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b Neath Port Talbot Hospital   (United Kingdom)

^c University Hospital of Hartlepool   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN; INCRETIN; LIRAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; ONSET AGE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSIDES; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84875184789     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835ec5f5     Document Type: Note

References (11)

1. Wannamethee SG, Shaper AG, Whincup PH, et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age of onset, diabetes duration and established and novel risk factors. Arch Intern Med 2011; 171: 404-410.
2. The ACCORD study Group. Long term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
3. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012; 9: 117-123. A very good review that looks at the evidence of the effects of the SGLT2 inhibitor class of compounds on cardiovascular outcomes. It also mentions the various ongoing and completed phase III trials on the different SGLT2 inhibitor compounds.
4. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
5. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabeteswho have inadequate glycaemic control with metformin: a randomised, double blind, placebo controlled trial. Lancet 2010; 375: 2223-2233.
6. Babu AR, Kim Y. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012; 5: 313-327. This review looks at the evidence for the effects of the various SGLT2 inhibitor compounds not just on cardiovascular disease, but also on glucose homeostasis, weight, kidney function, bone mineral density, adverse events and cancer incidence.
7. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52 week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 474-481.
8. Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects on incretin-based therapies. J Am Soc Hypertens 2012; 6: 163-168. This review discusses the effects of older hypoglycaemic agents, incretin-based therapies and the SGLT2 inhibitors on cardiovascular disease, with particular focus on blood pressure.
9. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 2012; 9: 95-102. An excellent article presenting the evidence for the clinical effects of GLP-1 receptor agonists on cardiovascular disease.
10. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results-a long term evaluation (LEADER). http://www.clinicaltrials.gov/ ct2/show/NCT01179048.
11. Exenatide Study of Cardiovascular Event Lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://www.clinicaltrials.gov/ct2/ show/NCT01144338.